BiotechTube

Tofacitinib 5 MG

ApprovedRecruiting
0 views this week 0 watching⚡ Active
Interest: 50/100
50
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Axial Spondyloarthritis

Conditions

Axial Spondyloarthritis

Trial Timeline

Nov 10, 2023 → Jun 1, 2026

NCT ID
NCT06112665

About Tofacitinib 5 MG

Tofacitinib 5 MG is a approved stage product being developed by Pfizer for Axial Spondyloarthritis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06112665. Target conditions include Axial Spondyloarthritis.

What happened to similar drugs?

5 of 20 similar drugs in Axial Spondyloarthritis were approved

Approved (5) Terminated (1) Active (15)
🔄Brodalumab + PlaceboKyowa KirinPhase 3
🔄Ixekizumab + PlaceboEli LillyPhase 3
🔄Ixekizumab + PlaceboEli LillyPhase 3
🔄SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 3
✅AdalimumabAbbVieApproved
🔄Adalimumab + Placebo + Open-label AdalimumabAbbViePhase 3
🔄adalimumab + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical
20
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06112665ApprovedRecruiting

Competing Products

20 competing products in Axial Spondyloarthritis

See all competitors
ProductCompanyStageHype Score
SUNPG1622 I dose + Placebo doseSun PharmaceuticalPhase 2
27
Brodalumab + PlaceboKyowa KirinPhase 3
40
Ixekizumab + PlaceboEli LillyPhase 3
40
Ixekizumab + PlaceboEli LillyPhase 3
40
SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 3
36
SHR-1314Jiangsu Hengrui MedicinePhase 1
29
UpadacitinibAbbViePre-clinical
33
AdalimumabAbbVieApproved
35
Adalimumab + Placebo + Open-label AdalimumabAbbViePhase 3
40
adalimumab + PlaceboAbbViePhase 3
40
TreatmentMerckPre-clinical
66
GolimumabMerckPhase 3
40
Tulisokibart + PlaceboMerckPhase 2
42
Secukinumab 150 milligram [Cosentyx]NovartisApproved
39
secukinumabNovartisPre-clinical
26
Secukinumab + PlaceboNovartisPhase 3
40
Secukinumab + Placebo + SecukinumabNovartisApproved
47
Secukinumab + Secukinumab and PlaceboNovartisPhase 3
40
Secukinumab/Adalimumab-BiosimilarNovartisPhase 3
40
Brodalumab 210 mg + PlaceboAmgenPhase 2
27